极早早产儿枸橼酸咖啡因停用时机的临床研究

doi:10.7499/j.issn.1008-8830.2108186

Abstract
Figure/Table
References(32)
Related Citation (15)
Read Tracking
Download Tracking

Download: PDF (538 KB) HTML
Export: BibTeX | EndNote (RIS) Supporting Info

Abstract Objective To study the clinical features and outcome of very preterm infants withdrawn from caffeine citrate at different time points. Methods A retrospective analysis was performed on the medical data of the preterm infants with a gestational age of <32 weeks, who were hospitalized in the Division of Neonatology, the Second Xiangya Hospital of Central South University, from January 1, 2016 to November 30, 2020. According to the time of withdrawal from caffeine citrate, the infants who met the study criteria were divided into the group with withdrawal before the last week of hospitalization and the group with withdrawal within the last week of hospitalization. The two groups were compared in terms of clinical features, features of citric caffeine use, length of hospital stay and hospital costs, change in the intensity of respiratory support, and preterm complications. Results A total of 403 preterm infants were enrolled, with 285 infants in the group with withdrawal before the last week of hospitalization and 118 infants in the group with withdrawal within the last week of hospitalization. There were no significant differences in clinical features between the two groups (P>0.05). Compared with the group with withdrawal before the last week of hospitalization, the group with withdrawal within the last week of hospitalization had a significantly longer duration of the use of caffeine citrate, a significantly shorter length of hospital stay, a significantly lower rate of increased intensity of respiratory support after withdrawal, and a significantly lower incidence rate of moderate or severe bronchopulmonary dysplasia (P<0.05). Conclusions A relatively long course of caffeine citrate treatment is more beneficial to the short-term clinical outcome of very preterm infants.

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	ZHANG Xue-Fei
	HE Xiao-Ri
	LI Wen
	WANG Tao
	HU Jin-Tao
	DONG Qing-Yi
	CHEN Ping-Yang

Key words： Caffeine citrate Withdrawal time Bronchopulmonary dysplasia Preterm infant

Received: 01 September 2021

Cite this article:

ZHANG Xue-Fei,HE Xiao-Ri,LI Wen et al. The timing of withdrawal from caffeine citrate in very preterm infants[J]. CJCP, 2021, 23(12): 1228-1233.

URL:

http://www.zgddek.com/EN/10.7499/j.issn.1008-8830.2108186 OR http://www.zgddek.com/EN/Y2021/V23/I12/1228

	Frey HA, Klebanoff MA. The epidemiology, etiology, and costs of preterm birth[J]. Semin Fetal Neonatal Med, 2016, 21(2): 68-73. PMID: 26794420. DOI: 10.1016/j.siny.2015.12.011.
	GBD 2019 Under-5 Mortality Collaborators. Global, regional, and national progress towards Sustainable Development Goal 3.2 for neonatal and child health: all-cause and cause-specific mortality findings from the Global Burden of Disease Study 2019[J]. Lancet, 2021, 398(10303): 870-905. PMID: 34416195. PMCID: PMC8429803. DOI: 10.1016/S0140-6736(21)01207-1.
	Eichenwald EC, Committee on Fetus and Newborn, American Academy of Pediatrics. Apnea of prematurity[J]. Pediatrics, 2016, 137(1): e20153757. PMID: 26628729. DOI: 10.1542/peds.2015-3757.
	Du LZ, Tong XM, Chen C, et al. Caffeine citrate for apnea of prematurity: a prospective, open-label, single-arm study in Chinese neonates[J]. Front Pediatr, 2020, 8: 76. PMID: 32219085. PMCID: PMC7078308. DOI: 10.3389/fped.2020.00076.
	Shenk EE, Bondi DS, Pellerite MM, et al. Evaluation of timing and dosing of caffeine citrate in preterm neonates for the prevention of bronchopulmonary dysplasia[J]. J Pediatr Pharmacol Ther, 2018, 23(2): 139-145. PMID: 29720916. PMCID: PMC5916442. DOI: 10.5863/1551-6776-23.2.139.
	Schmidt B, Roberts RS, Anderson PJ, et al. Academic performance, motor function, and behavior 11 years after neonatal caffeine citrate therapy for apnea of prematurity: an 11-year follow-up of the CAP randomized clinical trial[J]. JAMA Pediatr, 2017, 171(6): 564-572. PMID: 28437520. DOI: 10.1001/jamapediatrics.2017.0238.
	Mürner-Lavanchy IM, Doyle LW, Schmidt B, et al. Neurobehavioral outcomes 11 years after neonatal caffeine therapy for apnea of prematurity[J]. Pediatrics, 2018, 141(5): e20174047. PMID: 29643070. DOI: 10.1542/peds.2017-4047.
	Rostas SE, McPherson C. Caffeine therapy in preterm infants: the dose (and timing) make the medicine[J]. Neonatal Netw, 2019, 38(6): 365-374. PMID: 31712401. DOI: 10.1891/0730-0832.38.6.365.
	Doyle J, Davidson D, Katz S, et al. Apnea of prematurity and caffeine pharmacokinetics: potential impact on hospital discharge[J]. J Perinatol, 2016, 36(2): 141-144. PMID: 26562367. DOI: 10.1038/jp.2015.167.
	Darnall RA, Kattwinkel J, Nattie C, et al. Margin of safety for discharge after apnea in preterm infants[J]. Pediatrics, 1997, 100(5): 795-801. PMID: 9346978. DOI: 10.1542/peds.100.5.795.
	Coughlin K, Posencheg M, Orfe L, et al. Reducing variation in the management of apnea of prematurity in the intensive care nursery[J]. Pediatrics, 2020, 145(2): e20190861. PMID: 31941760. DOI: 10.1542/peds.2019-0861.
	Chung J, Tran Lopez K, Amendolia B, et al. Stopping caffeine in premature neonates: how long does it take for the level of caffeine to fall below the therapeutic range?[J]. J Matern Fetal Neonatal Med, 2020, 1-5. PMID: 32079435. DOI: 10.1080/14767058.2020.1729117. Epub ahead of print.
	方芳, 张军, 江帆. 重视小于胎龄儿病因识别及生长发育管理[J]. 中华儿科杂志, 2019, 57(9): 660-662. PMID: 31530349. DOI: 10.3760/cma.j.issn.0578-1310.2019.09.003.
	Jobe AH, Bancalari E. Bronchopulmonary dysplasia[J]. Am J Respir Crit Care Med, 2001, 167(3): 1723-1729. PMID: 11401896. DOI: 10.1164/ajrccm.163.7.2011060.
	Kero PO, M?kinen EO. Comparison between clinical and radiological classification of infants with the respiratory distress syndrome (RDS)[J]. Eur J Pediatr, 1979, 130(4): 271-278. PMID: 436851. DOI: 10.1007/BF00441363.
	16 中国医药教育协会超声医学专业委员会儿童超声学组,中华医学会儿科学分会超声医学筹备学组. 新生儿及婴儿颅脑超声专家共识[J]. 中华医学超声杂志(电子版), 2021, 18(6): 534-542. DOI: 10.3877/cma.j.issn.1672-6448.2021.06.002.
	Regenbogen E, Zhang SL, Yang J, et al. Epidemiological trends among preterm infants with apnea. A twelve-year database review[J]. Int J Pediatr Otorhinolaryngol, 2018, 107: 86-92. PMID: 29501318. DOI: 10.1016/j.ijporl.2018.01.036.
	Di Fiore JM, Poets CF, Gauda E, et al. Cardiorespiratory events in preterm infants: etiology and monitoring technologies[J]. J Perinatol, 2016, 36(3): 165-171. PMID: 26583939. DOI: 10.1038/jp.2015.164.
	Henderson-Smart DJ, De Paoli AG. Methylxanthine treatment for apnoea in preterm infants[J]. Cochrane Database Syst Rev, 2010(12): CD000140. PMID: 21154343. DOI: 10.1002/14651858.CD000140.pub2.
	He X, Qiu JC, Lu KY, et al. Therapy for apnoea of prematurity: a retrospective study on effects of standard dose and genetic variability on clinical response to caffeine citrate in Chinese preterm infants[J]. Adv Ther, 2021, 38(1): 607-626. PMID: 33180318. DOI: 10.1007/s12325-020-01544-2.
	Dix LML, van Bel F, Baerts W, et al. Effects of caffeine on the preterm brain: an observational study[J]. Early Hum Dev, 2018, 120: 17-20. PMID: 29604486. DOI: 10.1016/j.earlhumdev.2018.03.008.
	Schmidt B, Roberts RS, Davis P, et al. Long-term effects of caffeine therapy for apnea of prematurity[J]. N Engl J Med, 2007, 357(19): 1893-1902. PMID: 17989382. DOI: 10.1056/NEJMoa073679.
	Schmidt B, Anderson PJ, Doyle LW, et al. Survival without disability to age 5 years after neonatal caffeine therapy for apnea of prematurity[J]. JAMA, 2012, 307(3): 275-282. PMID: 22253394. DOI: 10.1001/jama.2011.2024.
	Schmidt B, Roberts RS, Davis P, et al. Caffeine therapy for apnea of prematurity[J]. N Engl J Med, 2006, 354(20): 2112-2121. PMID: 16707748. DOI: 10.1056/NEJMoa054065.
	Hennelly M, Greenberg RG, Aleem S. An update on the prevention and management of bronchopulmonary dysplasia[J]. Pediatric Health Med Ther, 2021, 12: 405-419. PMID: 34408533. PMCID: PMC8364965. DOI: 10.2147/PHMT.S287693.
	Henderson-Smart DJ, Davis PG. Prophylactic methylxanthines for endotracheal extubation in preterm infants[J]. Cochrane Database Syst Rev, 2010(12): CD000139. PMID: 21154342. DOI: 10.1002/14651858.CD000139.pub2.
	Katheria AC, Sauberan JB, Akotia D, et al. A pilot randomized controlled trial of early versus routine caffeine in extremely premature infants[J]. Am J Perinatol, 2015, 32(9): 879-886. PMID: 25607226. DOI: 10.1055/s-0034-1543981.
	Ji DB, Smith PB, Clark RH, et al. Wide variation in caffeine discontinuation timing in premature infants[J]. J Perinatol, 2020, 40(2): 288-293. PMID: 31758062. PMCID: PMC7222934. DOI: 10.1038/s41372-019-0561-0.
	Belkhatir K, Zivanovic S, Lumgair H, et al. Variations in preterm stabilisation practices and caffeine therapy between two European tertiary level neonatal units[J]. Acta Paediatr, 2020, 109(3): 488-493. PMID: 31512769. DOI: 10.1111/apa.15011.
	Long JY, Guo HL, He X, et al. Caffeine for the pharmacological treatment of apnea of prematurity in the NICU: dose selection conundrum, therapeutic drug monitoring and genetic factors[J]. Front Pharmacol, 2021, 12: 681842. PMID: 34381359. PMCID: PMC8350115. DOI: 10.3389/fphar.2021.681842.
	31 NICHD Neonatal Research Network. Moderately preterm infants with caffeine at home for apnea (MoCHA) trial[EB/OL]. ClinicalTrials. (2017-11-13)[2021-09-09].https://clinicaltrials.gov/show/NCT03340727
	贺婷, 廖正嫦, 丁颖, 等. 国产和进口枸橼酸咖啡因治疗早产儿呼吸暂停疗效的比较: 前瞻性随机双盲对照研究[J]. 中国当代儿科杂志, 2020, 22(7): 684-689. PMID: 32669161. PMCID: PMC7389628. DOI: 10.7499/j.issn.1008-8830.2003276.